ZYRTEC ALLERGY Drug Patent Profile

When do Zyrtec Allergy patents expire, and when can generic versions of Zyrtec Allergy launch?

Zyrtec Allergy is a drug marketed by Kenvue Brands and is included in two NDAs.

The generic ingredient in ZYRTEC ALLERGY is cetirizine hydrochloride. There are thirty-nine drug master file entries for this compound. One hundred and fifty-nine suppliers are listed for this compound. Additional details are available on the cetirizine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zyrtec Allergy

A generic version of ZYRTEC ALLERGY was approved as cetirizine hydrochloride by PADAGIS US on June 17^th, 2008.

Summary for ZYRTEC ALLERGY

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	7
Raw Ingredient (Bulk) Api Vendors:	109
Clinical Trials:	30
Patent Applications:	4,432
What excipients (inactive ingredients) are in ZYRTEC ALLERGY?	ZYRTEC ALLERGY excipients list
DailyMed Link:	ZYRTEC ALLERGY at DailyMed

Recent Clinical Trials for ZYRTEC ALLERGY

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Emory University	Phase 4
Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division	Phase 1
Indiana University	Phase 4

See all ZYRTEC ALLERGY clinical trials

Pharmacology for ZYRTEC ALLERGY

Drug Class	Histamine-1 Receptor Antagonist
Mechanism of Action	Histamine H1 Receptor Antagonists

US Patents and Regulatory Information for ZYRTEC ALLERGY

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Kenvue Brands	ZYRTEC ALLERGY	cetirizine hydrochloride	TABLET, ORALLY DISINTEGRATING;ORAL	022578-001	Sep 3, 2010		OTC	Yes	Yes
Kenvue Brands	ZYRTEC ALLERGY	cetirizine hydrochloride	TABLET;ORAL	019835-003	Nov 16, 2007		OTC	Yes	No
Kenvue Brands	ZYRTEC ALLERGY	cetirizine hydrochloride	TABLET;ORAL	019835-004	Nov 16, 2007		OTC	Yes	Yes

International Patents for ZYRTEC ALLERGY

See the table below for patents covering ZYRTEC ALLERGY around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	8307776
Yugoslavia	23782
Poland	134969

Supplementary Protection Certificates for ZYRTEC ALLERGY

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0663828	C300085	Netherlands		PRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103
0058146	SPC/GB01/052	United Kingdom		SPC/GB01/052:, EXPIRES: 20070205
0058146	2001C/045	Belgium		PRODUCT NAME: DICHLORHYDRATE DE LEVOCETIRIZINE; NAT RER. NO/DATE: 194 IS 90 F3 20011022; FIRST REG.: DE 49903.00.00 20010103

Market Dynamics and Financial Trajectory for ZYRTEC Allergy

Last updated: February 9, 2026

Market Position and Sales Performance

ZYRTEC Allergy (cetirizine) remains a leading antihistamine in the over-the-counter (OTC) allergy treatment segment. Johnson & Johnson, its current marketer following the 2021 sale of its prescription portfolio to UCB, maintains a dominant market share. In 2022, U.S. sales of ZYRTEC exceeded $950 million, representing approximately 20% of the total antihistamine market valued at around $4.75 billion (IQVIA).

The drug’s efficacy, safety profile, and brand recognition sustain consumer loyalty. Seasonal demand spikes during spring and fall, with sustained year-round retail sales in specific demographics.

Market Trends and Competitive Landscape

The global allergy medication market, worth approximately $12 billion as of 2022, exhibits moderate growth (CAGR of 4%) projected through 2027. The segment is highly competitive, with generics, new delivery forms, and non-drowsy formulations competing with ZYRTEC.

Key competitors include:

• Claritin (loratadine): Gained share due to similar efficacy and aggressive marketing.
• Allegra (fexofenadine): Known for rapid onset and non-drowsiness.
• Prescription-only options: Singulair (montelukast) and nasal sprays.

The shift toward non-drowsy, long-acting formulations favors ZYRTEC. The drug’s well-established OTC presence benefits from insurance reforms and flexible purchase channels.

Regulatory and Patent Landscape

ZYRTEC's patent protection expired in 2019 in the US, opening avenues for generics. Nevertheless, brand recognition sustains premium pricing, with OTC products priced typically between $10-15 for a 20-count package.

Regulatory controls transition toward OTC monographs, reducing the threat of formulation or label restrictions. No major regulatory hurdles are anticipated in the near term.

R&D and Pipeline Activities

Current research focuses on new delivery methods, such as dissolvable tablets and nasal sprays, aiming to improve convenience and patient adherence. No significant pipeline innovations targeting ZYRTEC's active ingredient are publicly disclosed, suggesting a focus on incremental improvements rather than radical innovations.

Financial Trajectory

• Revenue Streams: Primarily OTC sales, with over $900 million annually as of 2022.
• Margins: Gross margins approximate 60% due to low manufacturing costs of generic and OTC products.
• Growth Drivers: Seasonal demand, expanding allergy awareness, and potential new formulations.
• Risks: Patent expiry-driven generic competition and regulatory shifts.

Projections estimate a compound annual growth rate around 3-4% over the next five years, driven by seasonal sales and demographic shifts toward allergy-susceptible populations.

Pricing and Market Penetration

Pricing is stable, with slight increases aligned with inflation and marketing costs. Market penetration remains high in the U.S., with limited room for expansion in mature markets but emerging growth in developing regions.

Emerging Opportunities

Potential expansion into markets with underpenetrated OTC allergy products. Digital marketing channels and direct-to-consumer advertising could enhance brand presence.

Summary

ZYRTEC Allergy continues to generate steady revenue by leveraging brand strength and retail distribution. Facing generic competition, its financial outlook hinges on maintaining consumer loyalty through incremental innovation and market expansion.

---

Key Takeaways

• ZYRTEC remains a dominant OTC allergy drug with steady sales of nearly $1 billion in the U.S.
• The market is competitive, with key rivals like Claritin and Allegra, and growing generic options.
• Patent expiration opened the door for generics, but brand loyalty sustains premium pricing.
• Growth is driven by seasonal demand, demographic trends, and pipeline innovations focusing on formulations.
• Market risks include increased competition and regulatory evolutions affecting the OTC landscape.

---

FAQs

1. How does ZYRTEC compare to its competitors in market share and efficacy?
ZYRTEC holds about 20% of the OTC antihistamine market in the US, surpassing Claritin and Allegra in brand recognition. Clinical efficacy is comparable across leading brands; differentiation hinges on dosing convenience and perceived safety.

2. What is the impact of patent expiration on ZYRTEC’s sales?
Patent expiry in 2019 led to increased generic competition, which constrains price premiums but has not significantly eroded overall sales, thanks to strong brand loyalty and OTC status.

3. Are there any new formulations or delivery methods for ZYRTEC?
Research focuses on enhancing convenience, including dissolvable tablets and nasal sprays, but no major innovations have been introduced recently.

4. What are the main growth opportunities for ZYRTEC?
Expanding in emerging markets, leveraging digital marketing, and introducing incremental formulation improvements offer growth potential.

5. What risks could affect ZYRTEC’s future financial performance?
Key risks include competitive price erosion from generics, regulatory changes impacting OTC categories, and shifts in consumer preferences towards alternative or natural remedies.

---

Citations

1. IQVIA. "pharmaceutical market data," 2022.
2. U.S. Patent and Trademark Office. “Patent Expirations,” 2019.
3. Statista. “Global allergy medication market size,” 2022.
4. Johnson & Johnson. “Annual Financial Report,” 2022.
5. UCB. “Acquisition of ZYRTEC prescription portfolio,” 2021.